Summary
Gilead Sciences, Inc. (GILD) reported robust growth in its 2007 annual filing, driven primarily by its HIV product portfolio, which represented 84% of total product sales. Truvada and the newly launched Atripla were key contributors, with total HIV product sales increasing by 48% year-over-year to $3.14 billion. The company also saw significant growth in Hepsera and AmBisome. Royalty revenues increased by 12%, largely from Tamiflu sales, though the company anticipates a decline in these royalties in 2008 due to anticipated lower Tamiflu sales by Roche. Looking ahead, Gilead is focused on expanding its international presence and advancing its pipeline, with new drug applications filed for Viread in Hepatitis B and aztreonam lysine for inhalation in cystic fibrosis. The company also highlighted its ongoing investment in research and development, which increased by 54% in 2007, signaling a commitment to future growth through innovation and strategic acquisitions. Despite strong revenue growth, investors should note the potential impact of increased competition, regulatory scrutiny, and pricing pressures in the pharmaceutical market.
Financial Highlights
30 data points| Revenue | $4.23B |
| Cost of Revenue | $768.77M |
| Gross Profit | $3.46B |
| SG&A Expenses | $705.74M |
| Operating Expenses | $2.07B |
| Operating Income | $2.16B |
| Interest Expense | $63.18M |
| Net Income | $1.58B |
| EPS (Basic) | $0.85 |
| EPS (Diluted) | $0.82 |
| Shares Outstanding (Basic) | 1.86B |
| Shares Outstanding (Diluted) | 1.93B |
Key Highlights
- 1Total product sales reached $3.73 billion, a 44% increase year-over-year, primarily driven by strong performance in HIV products.
- 2HIV products generated $3.14 billion in sales, marking a 48% increase, with Truvada and Atripla being the main drivers.
- 3Atripla, a single-tablet HIV regimen, saw substantial sales growth of 339%, reflecting strong market uptake in the U.S. and expanding into European markets.
- 4Royalty revenues increased by 12% to $468.2 million, primarily from Tamiflu, though a decline is expected in 2008.
- 5The company filed new drug applications for Viread for Hepatitis B and aztreonam lysine for inhalation for cystic fibrosis, signaling pipeline progression.
- 6Research and Development expenses increased by 54% to $591.0 million, underscoring Gilead's commitment to innovation and pipeline development.
- 7Gilead expanded its international operations by establishing new subsidiaries and strengthened its manufacturing capabilities through acquisitions.